The head of the trade association PhRMA, John Castellani, today took umbrage at the AHIP's complaints about the high cost of Sovaldi where they termed it "unsustainable". Castellani said they were being "penny wise and pound follish to focus solely on the price of a new medicine while completely ignoring the value it provides to patients and the health care system broadly". He further noted that "curing hepatitis C not only dramatically improves patients' lives, but it has the potential to save the US healthcare system as much as $9 billion per year." See the PharmaTimes.
Posted by Bruce Lehr June 2nd 2014.